This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

16 May 2011

Astellas & BioFocus Ink Target Discovery Deal

BioFocus has signed a collaboration agreement with Tokyo-based Astellas Pharma focused on discovering novel targets in the field of CNS disorders.

BioFocus and Astellas Pharma have entered into a collaboration agreement to focus on discovering novel targets in the field of central nervous system (CNS) disorders.


BioFocus, a service division of Galapagos, will utilize its SilenceSelect target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.


"We are delighted to support Astellas Pharma in its research,” said Dr. Chris Newton, senior vice president Galapagos Services and managing director BioFocus. “Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technolo

Related News